1 / 1

Intensive vs. Standard Lipid-Lowering in Treatment-Resistant Hypertension

Study on cumulative incidence of primary endpoint in patients with treatment-resistant hypertension comparing Atorvastatin 10mg and 80mg. Primary outcomes include death from CHD, non-fatal non-procedure-related MI, resuscitation after cardiac arrest, and fatal or non-fatal stroke. Findings published in European Heart Journal 2014 by Bangalore et al.

penelope-duncan
Télécharger la présentation

Intensive vs. Standard Lipid-Lowering in Treatment-Resistant Hypertension

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Atorvastatine 10 mg Cumulative incidence of primary endpoint with intensive vs. standard lipid-lowering in treatment-resistant hypertension 30 Atorvastatine 80 mg Primary endpoint: death from CHD, non-fatal non-procedure-related MI, resuscitation after cardiac arrest ,fatal or non-fatal stroke 20 Primary outcome (%) 10 0 0 1 2 3 4 5 Follow-up (years) Bangalore et al., Eur Heart J 2014

More Related